Overview


According to FutureWise analysis, the market for Frasier Syndrome is expected to grow with a CAGR of 8.82% over the forecast period 2024-2032, and reach a market value of US$ 0.27 Billion by 2031. 

Frasier Syndrome, also known as Frasier's syndrome, is a rare genetic disorder primarily affecting the kidneys and genitalia. It is named after the pediatric nephrologist Julianne Frasier, who first described it. Mutations in the WT1 gene cause Frasier Syndrome. This gene delivers instructions for making a protein essential for developing the kidneys and the reproductive organs. Individuals with Frasier Syndrome often have abnormalities in their kidneys. These can include a condition known as focal segmental glomerulosclerosis (FSGS), which affects the kidney's filtering units (glomeruli). Over time, this can lead to kidney dysfunction. Some individuals with Frasier Syndrome may experience hormonal imbalances. This can affect puberty and the development of secondary sexual characteristics.

Diagnosis of frasier syndrome relies on various types of tests, including genetic testing and biochemical testing. Genetic testing is a pivotal diagnostic tool for frasier syndrome. It involves analyzing an individual's DNA to identify any mutations or alterations in the WT1 gene. This test provides a direct link to the underlying genetic cause of the syndrome. By pinpointing specific genetic abnormalities, healthcare professionals can confirm the diagnosis and provide useful information regarding the inheritance pattern of the disorder, aiding in genetic counseling. Biochemical testing is another essential component of diagnosing Frasier Syndrome. This type of testing involves analyzing the levels of specific molecules, such as hormones, in the blood or urine.

FutureWise Market Research has published a report that provides an insightful analysis frasier syndrome market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts frasier syndrome market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Thermo Fisher Scientific
  • PerkinElmer
  • Hoffmann-La Roche
  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Siemens Healthineers
  • Danaher
  • Grifols
  • Ortho Clinical Diagnostics
  • Novartis
  • Quest Diagnostics
  • Myriad Genetics
  • Luminex
  • QIAGEN
  • BioMerieux
  • Laboratory Corporation of America
  • Genomic Health
  • NeoGenomics
  • Ambry Genetics
  • Invivoscribe

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Frasier Syndrome Market:

  • In September 2022, Quest Diagnostics partnered with Grail to broaden patient access to multi-cancer early detection (MCED) testing. This will aid in the diagnosis of cancers associated with Frasier syndrome.

  • In March 2022, Thermo Fisher Scientific launched the TaqMan Allelic Discrimination Kit, a polymerase chain reaction-based test for detecting gene mutations associated with Frasier syndrome. The test provides accurate and rapid results.

The rising incidences of Frasier syndrome are expected to be a significant driver for market expansion. This increase in cases may be attributed to improved diagnostic capabilities and heightened awareness among healthcare professionals and the public. As early detection becomes more prevalent, individuals with Frasier syndrome may receive timely intervention and management, potentially leading to an increased demand for specialized treatments and therapies. Furthermore, advancements in genetic research and diagnostics are likely to play an integral role in identifying and understanding this rare genetic disorder, fostering the development of targeted therapeutic approaches. These factors contribute to the optimistic perspective for market expansion over the forecast period. Moreover, the heightened awareness among both healthcare professionals and the general public regarding Frasier syndrome is a key driver propelling early diagnosis and intervention. With improved understanding and recognition of the disorder's symptoms and risk factors, healthcare providers are better equipped to identify potential cases, enabling swifter diagnostic procedures. Additionally, increased public awareness encourages individuals and families to seek medical attention sooner, especially when symptoms manifest, facilitating prompt evaluation and intervention. Therefore, this approach significantly enhances the likelihood of timely and effective management, potentially leading to improved patient results and a higher quality of life for those affected by Frasier syndrome. However, reimbursement challenges stand as a major restraint in the growth of the Frasier syndrome market. Given the rarity of this genetic disorder, obtaining appropriate reimbursement for diagnostic tests, treatments, and specialized care might be an arduous task. The intricacies and growing nature of healthcare policies further compound this issue. Without adequate financial support, healthcare providers may be hesitant to invest in the resources required to diagnose and manage Frasier syndrome effectively. Also, pharmaceutical companies may face hurdles in garnering the necessary funding for research and development, potentially limiting the availability of targeted therapies. This impediment may ultimately hinder the accessibility and affordability of essential treatments for individuals with Frasier syndrome, potentially constraining market growth.

By Test Type

  • Genetic Testing
  • Biochemical Testing
  • Others

By End User

  • Hospitals
  • Diagnostic Centers
  • Research Institutes 
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to the accuracy and specificity of genetic tests, surging incidences of Frasier syndrome, high awareness, developed healthcare infrastructure, and rising healthcare expenditure in the region is anticipated to drive the growth of the target market over the projection period. In addition, increased research and development activities, technological advancement in diagnostic methods, and favorable reimbursement policies are further driving the market expansion. Also, partnerships and collaborations, product launches, and approvals are factors further propelling the market growth in the US during the projection period. For instance, in January 2021, PerkinElmer launched the CLASSIX Frasier Panel, the first complete NGS-based panel for Frasier syndrome diagnosis. It detects sequence and copy number alterations in WT1 and Frasier syndrome-associated genes.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Frasier Syndrome Market By Test Type, By End User, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Frasier Syndrome Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Frasier Syndrome Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Frasier Syndrome Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Frasier Syndrome Market, By Test Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Genetic Testing
        2. Biochemical Testing
        3. Others

  • 8.  Frasier Syndrome Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals
        2. Diagnostic Centers
        3. Research Institutes
        4. Others

  • 9.  North America Frasier Syndrome Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 10.  Latin America Frasier Syndrome Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 11.  Europe Frasier Syndrome Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 12.  Asia Pacific Frasier Syndrome Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 13.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 14.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. PerkinElmer
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Hoffmann-La Roche
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Abbott Laboratories
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Bio-Rad Laboratories
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Siemens Healthineers
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Danaher
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Grifols
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Ortho Clinical Diagnostics
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Novartis
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Quest Diagnostics
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Myriad Genetics
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Luminex
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. QIAGEN
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. BioMerieux
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. Laboratory Corporation of America
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. Genomic Health
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview
        18. NeoGenomics
           18.1. Company Overview
           18.2. Product Portfolio
           18.3. SWOT Analysis
           18.4. Financial Overview
           18.5. Strategic Overview
        19. Ambry Genetics
           19.1. Company Overview
           19.2. Product Portfolio
           19.3. SWOT Analysis
           19.4. Financial Overview
           19.5. Strategic Overview
        20. Invivoscribe
           20.1. Company Overview
           20.2. Product Portfolio
           20.3. SWOT Analysis
           20.4. Financial Overview
           20.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients